Eckert & Ziegler Bebig SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Eckert & Ziegler Bebig SA Announces SFDA Approval for Brachytherapy MultiSource HDR Afterloading System
Eckert & Ziegler Bebig SA announced that the Chinese State Food and Drug Administration (SFDA) has approved its MultiSource HDR afterloading system for brachytherapy. MultiSource is an afterloader designed for the range of HDR brachytherapy applications for cancer treatment. HDR brachytherapy is a form of radiotherapy in which cancer is treated by irradiation from a short distance.
Latest Developments for Eckert Ziegler BEBIG SA
Latest Key Developments in Healthcare
- Addus HomeCare Corp announces closing of its previously announced purchase of fifteen offices in New Mexico
- Omnicare Inc authorizes share repurchase; increases dividend
- Sogo Rinsho Holdings Co Ltd raises annum dividend forecasts for FY 2014
- Northstar Healthcare Inc signs agreement with PI Financial to raise up to $5,000,000 through brokered private placement
- Share this
- Digg this